1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1516
2Wieckowska A, McCulloug AJ, and Feldstein AE. Noninvasive diagnosis and montoring of nonalcoholic steatohepatitis: Present and fu ture[ J]. Hepatology, 2007,46(2) : 582 - 589.
3Baranova A, Younossi ZM. The future is around the comer: Noninvasie diagnosis of progressive nonalcoholic steatohepatitis[ J]. Hepatology, 2008,47 ( 2 ) : 373 - 375.
5Ekstedt M, Franzen LE, Mathiesen UL, et al. Long - term follow - up of patients with NAFLD and elevated liver enzymes[ J]. Hepatology, 2006,44 (4) : 865 - 873.
6Yamazaki Y, Kakizaki S, Horiguchi N, et al. The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non - alocbolic steatobepatitis[ J]. Gut, 2007, 56(4) : 565 - 574.
7Mofrad P, Contos M J, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values[J]. Hepatology, 2003, 37(4):1286-1292.
8Kunde SS, Lazenby AJ, Clements RH, et al. Spectum of NAFLS and diagnostic implications of the proposed new normal range for serum ALT in obese women [ J ]. Hepatology, 2005,42 (2) : 650 - 656.
9Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis[ J]. Hepatology, 1999,50(5): 1356 - 1362.
7Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
8Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
9Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
10Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1516
2Nakano R, Kurasaki E, Shimya A, et al. Antaggonism of PPARr prevents high-fat diet induced obesity in vivo [J]. Biochemical Pharmacology, 2006,72 (1) : 42-52.
3Merat S, Aduli M,Kazemi R,et al. Liver histology changes in nonalcoholic steato hepatitis after one year of treatment with probucol[J]. Dig Dis Sci,2008,53(8):2246-2250.
